virginio chiodini - Academia.edu (original) (raw)

Papers by virginio chiodini

Time-dependent Cox model adjusted by age, sex, comorbidities (Charlson index) and histor... more Time-dependent Cox model adjusted by age, sex, comorbidities (Charlson index) and history of E-COPD in the three-year pre-index period.</p

Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary... more Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. The index event is not included.'Drugs used to treat COPD exacerbation. ''Drugs for obstructive airway diseases - Anatomical therapeutic Chemical (ATC) Classification R03 -. +Drugs for the cardiovascular system - ATC C -. ∼Pulmonary function tests, respiratory pattern examination, 6-minute walking test, chest computed tomography or radiography, C-reactive protein and sputum examination.</p

It includes spirometry and lung volumes, body plethysmography, diffusion capacity, bronc... more It includes spirometry and lung volumes, body plethysmography, diffusion capacity, bronchial provocation and reversibility testing.Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period.1 p<0.05 vs group A, 2 p<0.05 vs group B.</p

Women expenditure (€/patient-year) by age classes.</p

Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary... more Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. The index event is not included. SD = standard deviation.'Age and sex adjusted rate per one person-year.1p<0.05 vs group A, 2 p<0.05 vs group B.</p

Distribution of overall costs (€/patient-year) by age classes, according to the three ma... more Distribution of overall costs (€/patient-year) by age classes, according to the three main cost categories: hospitalization, drug therapy and outpatient.</p

Patient distribution of mean healthcare costs (€/patient-year).</p

Blood, 2014

Introduction. The incidence of multiple myeloma (MM) is increasing in particular due to the aging... more Introduction. The incidence of multiple myeloma (MM) is increasing in particular due to the aging of the population.In the last 15 years, stem cell transplantation and novel agents have increased the remission rates and improved survival. The aim of the present work is to assess the epidemiologic burden of treated patients from population-based data. Methods. The Regional Health Service (RHS) of Lombardy covers around 10 million people. Administrative datasets available within the Lombardy RHS included: demographic data, hospital discharges, pharmaceutical prescriptions, and outpatient claims. Since 2000 these archives were organized into a data warehouse named DENALI. A distinguishing feature of DENALI is the probabilistic reconstruction of links to match the data of different datasets belonging to the same person. The initial study population was selected from DENALI and involved all those individuals who during the period 2003-2009 had at least one hospital discharge for MM and a...

Blood, 2014

Introduction. In the last 15 years, stem cell transplantation and novel agents have increased the... more Introduction. In the last 15 years, stem cell transplantation and novel agents have increased the remission rates and improved survival in multiple myeloma (MM) but they have also affected the cost of myeloma treatment. The aim of the present study was to describe direct healthcare costs in treating MM patients from a 2003-2009 population-based study. Methods. Since 2000the Regional Health Service (RHS) of Lombardy, covering around 10 million people, systematically organizes its healthcare administrative archives into a data warehouse named DENALI. A distinguishing feature of DENALI is the probabilistic reconstruction of links to match the data of different datasets belonging to the same person. The study population of the present study was selected from DENALI and involved all those individuals who during the period 2003-2009 had at least one hospital discharge for MM and at least one MM specific drug prescription among melphalan, bortezomib, cyclophosphamide, thalidomide, doxorubi...

Farmeconomia. Health economics and therapeutic pathways, 2011

Aims: this study wants to estimate the economic burden of incident Acute Myocardial Infarction (A... more Aims: this study wants to estimate the economic burden of incident Acute Myocardial Infarction (AMI) registered in Lombardy (about 9.2 million residents). Method and results: a longitudinal study was conducted using a Data Warehouse (DENALI) that organised Healthcare Administrative databases of Lombardy related to eligibility criteria, hospital discharges (HDs), pharmaceutical and outpatient claims of citizens. All individuals with a HD for a first event of AMI during 2003 were identified and followed for 12 months. During 2003 12,049 individuals (64% males, mean age 70 +/-13 y.o.) had a HD for incident AMI. The total cost during the first year was € 163 million, corresponding to the 1% of the healthca re budget of Lombardy. The monthly cost in the first year was € 1,249 per person (77% attributable to HDs, 15% to pharmaceuticals and 8% to outpatient care). While most of the uptake of drugs used in secondary prevention was quick and happened in the first 3 months after the index eve...

Farmeconomia. Health economics and therapeutic pathways, 2011

Europace, 2016

Introduction: Cryoablation has been shown to be safe and effective technology for the ablation of... more Introduction: Cryoablation has been shown to be safe and effective technology for the ablation of cardiac arrhythmias. This study reports for the first time the efficacy and safety of a new catheter designed to create segmental linear lesions in both atria. The ArcticLine TM catheter employs an 11F 35mm long deflectable ablation segment. The surface is cooled by the passage of liquid nitrous oxide. Electrodes on either side of the ablation zone allow for 3D navigation and electrical recording. Methods: Via a 12F deflectable sheath the catheter was used to ablate the left (L) and right (R) isthmus and to place LA roof linear lesions (LL) connecting the PVs. The integrity of the lesions was assessed by paced activation, 3D mapping and histopathology following 4 weeks of recovery. Results: In 3 canines, left and right CTI were accomplished with 2.75 + 1.0 cryo applications. Left atria 19 + 2.8/atria LL were placed. Bi-directional conduction block was documented across both isthmus. Trichrome staining and histology revealed contiguous transmural lesions with an average lesion segmental length of 27.7 + 3.7mm, width 7.3 + 1.7mm and depth 2.1 + 0.9 mm and total contiguous length of 105.1mm (shown in the figure Panel A RA isthmus and Panel B LA LL and Left Isthmus Line). Conclusion: The ArcticLine TM catheter is capable of creating transmural and contiguous lesions in both the right and left atria. Ablation of the right and left isthmus lines were successfully created with the ArcticLine TM. Transmural contiguous ablations in the left atria were placed connecting the PVs.

Global Journal of Epidemiology and Public Health, 2014

PLoS ONE, 2014

Objective: To assess the epidemiologic and economic burden of diabetes mellitus (DM) from a longi... more Objective: To assess the epidemiologic and economic burden of diabetes mellitus (DM) from a longitudinal population-based study. Research Design and Methods: Lombardy Region includes 9.9 million individuals. Its DM population was identified through a data warehouse (DENALI), which matches with a probabilistic linkage demographic, clinical and economic data of different Healthcare Administrative databases. All individuals, who, during the year 2000 had an hospital discharge with a IDC-9 CM code 250.XX, and/or two consecutive prescriptions of drugs for diabetes (ATC code A10XXXX) within one year, and/or an exemption from co-payment healthcare costs specific for DM, were selected and followed up to 9 years. We calculated prevalence, mortality and healthcare costs (hospitalizations, drugs and outpatient examinations/visits) from the National Health Service's perspective. Results: We identified 312,223 eligible subjects. The study population (51% male) had a mean age of 66 (from 0.03 to 105.12) years at the index date. Prevalence ranged from 0.4% among subjects aged #45 years to 10.1% among those .85 years old. Overall 43.4 deaths per 1,000 patients per year were estimated, significantly (p,0.001) higher in men than women. Overall, 3,315J/patient-year were spent on average: hospitalizations were the cost driver (54.2% of total cost). Drugs contributed to 31.5%, outpatient claims represented 14.3% of total costs. Thirty-five percent of hospital costs were attributable to cerebro2/cardiovascular reasons, 6% to other complications of DM, and 4% to DM as a main diagnosis. Cardiovascular drugs contributed to 33.5% of total drug costs, 21.8% was

Women expenditure (€/patient-year) by age classes.</p

Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary... more Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. The index event is not included. SD = standard deviation.'Age and sex adjusted rate per one person-year.1p<0.05 vs group A, 2 p<0.05 vs group B.</p

Patient distribution of mean healthcare costs (€/patient-year).</p

Blood, 2014

Farmeconomia. Health economics and therapeutic pathways, 2011

Europace, 2016

Global Journal of Epidemiology and Public Health, 2014

PLoS ONE, 2014